Why the study?
Does a 24-hour infusion of diltiazem reduce myocardial ischemia and arrhythmias in patients undergoing elective coronary bypass grafting compared to nitroglycerin?
Does a 24-hour infusion of diltiazem reduce myocardial ischemia and arrhythmias in patients undergoing elective coronary bypass grafting compared to nitroglycerin?
Perioperative infusion of diltiazem provides superior anti-ischemic and anti-arrhythmic protection compared to nitroglycerin in patients undergoing elective coronary bypass grafting.
Answers are grounded in this paper and cite their sources.
May favor diltiazem over nitroglycerin after CABG; leaves open need for RCT confirmation.
In 91 patients undergoing elective coronary bypass grafting, the anti-ischemic and anti-arrhythmic efficacy of a 24-hour infusion of either the calcium antagonist diltiazem (0.1 mg/kg per h, n = 44) or nitroglycerin (1 micrograms/kg per min, n = 47) were compared. Myocardial ischemia was diagnosed by Holter monitoring and the repeated assessment of 12-lead ECG and serum enzyme levels and defined as a transient ischemic event, transient coronary spasm or myocardial infarction. The two groups did not differ with respect to preoperative and operative data. Postoperatively, the average heart rate and pulse pressure rate were significantly lower in the diltiazem group. The incidence of postoperative atrial fibrillation (4.5 vs 19.1%, P < 0.01), transient coronary spasm (2.3 vs 11.4%, P < 0.05) and myocardial infarction (4.5 vs 8.5%, not significant) and the frequency of ventricular premature couplets/h (12.1 +/- 4.5 vs 18.1 +/- 5.1, P < 0.05) and ventricular runs/h (2.5 +/- 0.8 vs 6.5 +/- 2.8, P < 0.05) were lower in the diltiazem as compared to the nitroglycerin group. In addition, diltiazem-treated patients had significantly lower postoperative peak values of creatine kinase-MB (19.3 +/- 11.6 vs 29.3 +/- 20.6, P < 0.05). In conclusion, perioperative infusion of diltiazem is effective in reducing the incidence and extent of arrhythmias and myocardial ischemia in patients undergoing elective coronary bypass grafting as compared to patients receiving nitroglycerin.
No takes yet. Share an insight, caveat, or question.
Hannes et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: